During a lead-in period , patients received twice daily ( b.i.d. ) axitinib @ mg ( n = @ ) or @ mg ( n = @ ) for @ days followed by a @-day dosing interruption ; serial ( @ ) FLT-PET scans were performed before day @ and on days @ , @ , and @ .